All In Biotech

Drug Trial Radar · NCT05361655

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Real-World Treatment Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as 1st Line Therapy in Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

2,888

Actual

Start

Sep 1, 2021

Primary completion

Sep 1, 2021

Study completion Sep 1, 2021

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
May 5, 2022

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.

Conditions

  • Metastatic Breast Cancer

Interventions

  • Palbociclib + an aromatase inhibitorDrug

    Palbociclib + an aromatase inhibitor therapy

  • Aromatase inhibitorDrug

    Aromatase inhibitor therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Postmenopausal Female or Male Participants With Metastatic Breast CancerTime frame: From index date to death due to any cause or censoring date of 30-Sep-2020 (approximately up to 68 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • 10017

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.